Tech & Pharma

MasterCard Launches Innovation R&D Center In Singapore

MasterCard has launched a new innovation R&D center in Singapore to research into new payment solutions.

January 30, 2012

Takeda’s Orteronel Enters Phase III Clinical Trials For Prostate Cancer

Takeda has initiated enrollment of patients in Japan for the two ongoing global Phase III clinical trials for its anti-prostate cancer investigational agent, orteronel (TAK-700).

January 30, 2012

Watson Pharma Buys Ascent Pharmahealth For AU$375 Million

Watson Pharmaceuticals, Inc. has acquired generics pharmaceutical maker Ascent Pharmahealth for AU$375 million.

January 24, 2012

A*STAR, GE Global Research To Develop Cancer Imaging Technologies

GE Global Research and A*STAR have signed an agreement to develop clinical cancer imaging technologies and diagnostics.

January 23, 2012

China Approves World’s First Hepatitis E Vaccine

China has approved the world’s first hepatitis E virus (HEV) vaccine this month, said China’s Ministry of Science and Technology.

January 23, 2012

Amerigen Signs MOU With VIWA Pharma, Shanghai Fosun Omni Pharma

Amerigen Pharmaceuticals Limited has signed MOUs with two companies involved in the development of generic medicine in China.

January 16, 2012

BIOTRONIK Opens New Asia Pacific Headquarters in Singapore

Centrally located office in Singapore is set to be the launching pad for significant BIOTRONIK business development in the Asia Pacific region.

January 16, 2012

Sinovac: Phase III Clinical Trial For Hand, Foot And Mouth Disease Vaccine

Chinese biopharmaceutical company Sinovac Biotech Ltd. has begun the Phase III clinical trial for its proprietary inactivated EV71 vaccine against hand, foot and mouth disease (HFMD).

January 13, 2012

Australian Study To Assess Sativex As Cannabis Withdrawal Drug

Researchers are studying whether the pharmaceutical drug Sativex – registered for pain relief in multiple sclerosis patients – can help people better manage cannabis withdrawal symptoms as well.

January 11, 2012

SFJ Pharma To Conduct Phase III Trial Of Pfizer’s Axitinib Adjuvant Treatment In Asia

SFJ Pharma Ltd. will conduct a Phase III clinical trial in Asia of Pfizer’s axitinib for the adjuvant treatment of patients at high risk of recurrent renal cell carcinoma following nephrectomy.

January 10, 2012